What does the research say about tau pathology?
Tau pathology refers to the abnormal hyperphosphorylation and aggregation of the microtubule-associated protein tau, a hallmark of Alzheimer's disease and related tauopathies. This page summarises representative research
What does the research say about tau pathology?
Tau pathology is the term for the abnormal hyperphosphorylation and aggregation of the microtubule-associated protein tau, which forms neurofibrillary tangles and is a defining neuropathological feature of Alzheimer's disease (AD) and related tauopathies such as frontotemporal lobar degeneration (FTLD), corticobasal degeneration syndrome (CBS), and progressive supranuclear palsy (PSP) [2][4]. In the research literature, tau pathology is studied as a driver of neurodegeneration alongside amyloid-β accumulation, oxidative stress, neuroinflammation, mitochondrial dysfunction, and cholinergic deficits [2]. The evidence block for this page does not provide a sequence, formula, or molecular weight for tau; those identifiers are therefore not stated here.
The work centres on the microtubule-associated protein tau and its post-translational regulation, particularly hyperphosphorylation, as well as downstream pathways including synaptic plasticity, neuroinflammation, and mitochondrial quality control [2][6].
Research Studies
Natural medicines and tau-related mechanisms in Alzheimer's disease models
A bibliometric analysis and narrative review mapped natural medicine research for AD from 2001 to 2025 and examined representative mechanistic evidence [1]. The review reported that natural medicines have been widely investigated for AD, but the relationship between bibliometric themes and experimental evidence remains insufficiently characterised [1]. Findings were drawn from original experimental studies, and the review did not establish clinical efficacy for tau pathology [1].
Medicinal plants and tau hyperphosphorylation in preclinical and clinical studies
A comprehensive review synthesised evidence from in vitro, in vivo, and clinical studies on 15 medicinal plants and 21 active compounds with therapeutic relevance to AD [2]. Inclusion required reported neuroprotective activity in at least one AD-related pathway, including tau hyperphosphorylation [2]. The review noted that current FDA-approved therapies provide only modest symptomatic relief, underscoring the need for multi-targeted alternatives [2]. The evidence for tau-directed effects was largely preclinical; clinical findings were limited [2].
Targeted neuronal reprogramming and tauopathy in the P301S mouse model
In the P301S mouse model of tauopathy, targeted and intermittent expression of Yamanaka factors in hippocampal neurons was investigated for its ability to restore cognitive function and neural network integrity [3]. Controlled expression increased excitatory synaptic markers and rescued memory and neural synchrony [3]. This finding is animal-only and does not establish effects in humans [3].
Davunetide (AL-108) and predicted tauopathies in a pilot clinical study
A pilot study (NCT01056965) evaluated davunetide (NAP, AL-108) in patients with a tauopathy, including FTLD with predicted tau pathology, CBS, or PSP [4]. The primary objective was preliminary safety and tolerability; secondary objectives included short-term changes at 12 weeks in clinical, functional, and biomarker measurements such as cerebrospinal fluid (CSF) tau levels, eye movements, and brain MRI [4]. The study was designed to obtain preliminary data, not to confirm efficacy [4].
NAD+-mitophagy axis and neurodegeneration in aging models
A combined artificial intelligence–wet lab approach identified a pivotal role of the NAD+-mitophagy axis in aging and neurodegeneration [5]. The work hypothesised that age-dependent impairment of this axis contributes to brain aging and neurodegeneration [5]. This finding is reported as a fact from the cited paper and is not specific to tau pathology [5].
Biochemical modulators of synaptic plasticity in Alzheimer's disease
A review of biochemical modulators of synaptic plasticity described synaptic dysfunction as the earliest and most critical pathological feature of AD, directly contributing to cognitive decline [6]. The review discussed how the collection of molecular and biochemical modulators governing synaptic plasticity is disrupted in AD [6]. This evidence is review-level and does not report original tau-specific experiments [6].
Comparison of tau-related outcome measures in the davunetide pilot study
| Outcome measure | Time point | Purpose |
|---|---|---|
| Safety and tolerability | Primary objective | Preliminary data in tauopathy patients [4] |
| CSF tau levels | 12 weeks | Short-term change from baseline [4] |
| Eye movements | 12 weeks | Short-term change from baseline [4] |
| Brain MRI measurements | 12 weeks | Short-term change from baseline [4] |
Model systems used in tau pathology research
| Model | Example | Evidence type |
|---|---|---|
| In vitro | Cell-based assays of tau hyperphosphorylation [2] | Preclinical [2] |
| In vivo (animal) | P301S mouse model of tauopathy [3] | Animal-only [3] |
| Clinical | Pilot study in predicted tauopathies [4] | Preliminary safety and tolerability [4] |
If you are reading this for personal health reasons
The materials described on this page are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Research Trends and Mechanistic Insights Into Natural Medicines for Alzheimer's Disease: A Bibliometric Analysis and Narrative Review
- [2] Translational potential of medicinal plants for Alzheimer's disease: integrated evidence from molecular mechanisms to preclinical and clinical findings
- [3] Targeted neuronal reprogramming rescues memory and neural synchrony in Alzheimer's disease
- [4] Davunetide (AL-108) in Predicted Tauopathies - Pilot Study
- [5] A combined artificial intelligence-wet lab approach identifies a pivotal role of the NAD+-mitophagy axis on aging and neurodegeneration
- [6] Biochemical modulators of synaptic plasticity: New horizons in Alzheimer's disease treatment